Multicenter Randomized Study of Two Once Daily Regimens in the Initial Management of Community-Acquired Respiratory Tract Infections in 163 Children: Azithromycin versus Ceftibuten
作者:
K. Galova,
S. Sufliarska,
Z. Kukovac,
A. Danisovicova,
I. Hrachova,
S. Grausova,
I. Marinova,
S. Krizan,
K. Stopkova,
A. Stahorska,
K. Durcanska,
J. Raskova,
I. Krupova,
V. Krčméry, Jr.,
期刊:
Chemotherapy
(Karger Available online 1996)
卷期:
Volume 42,
issue 3
页码: 231-234
ISSN:0009-3157
年代: 1996
DOI:10.1159/000239448
出版商: S. Karger AG
关键词: Ceftibuten;Azithromycin;Pediatric respiratory tract;infections Once daily regimens
数据来源: Karger
摘要:
In a randomized trial, we compared the efficacy and toxicity of azithromycin and ceftibuten once daily in the initial (empiric) therapy of proven or suspected community-acquired respiratory tract infections (CARTI) in 163 pediatric patients: 95.5% of those treated with azithromycin and 83.6% of those treated with ceftibuten were cured or improved. Streptococcus pneumoniae was more frequently eradicated in the azithromycin than in the ceftibuten group, whereas gram-negative bacilli were more susceptible to ceftibuten. Elimination rates for Staphylococcus aureus and Haemophilus influenzae were similar; adverse reactions did not differ in both arms. Thus, azithromycin was more effective but equally safe than ceftibuten in the initial therapy of pediatric CARTI.
点击下载:
PDF
(1105KB)
返 回